Get started

Equillium, Inc.

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

EQ chart

Key stats

Market capitalization
25.581MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.5283USD
Net income
−62.428MUSD
Revenue
15.759MUSD
Shares float
18.468M
Beta
1.33

About Equillium, Inc.

Sector
Health Technology
Industry
Biotechnology
CEO
Bruce D. Steel
Website
equilliumbio.com
Headquarters
La Jolla
Employees (FY)
36
Founded
2017
ISIN
US29446K1060

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March, 2017 and is headquartered in La Jolla, CA.

Ideas

Monster move is comingPrice has started to diverge from the moving averages on higher TFs. Nice volume accumulation. Notice how drop to 4 got bought up quickly. It tested supply zone at 6 and continues to push higher. Now news likely to hit any day to spike it to 10 or even 13.
Long
5
EQ Watch for Resistance Breakout. Bullish FridayEQ reached top mover status as a gainer one day and a loser the following day. Thursday, EQ was up +1.49% pre-market. I predict stock moves at a steady pace toward $24 price target. EQ is a mall biotech company researching Alzheimer's medicine. Healthcare is our third-largest sector ($6.2 T).
Long
1
EQ Bullish Target $24EQ soared after news on Alziemers drug. Following the spike in volume (OBV), there is a pullback. Now, I predict a bullish rise to the $24 target. Please always do your own research. This is not advice. I'm here to learn. Thoughts?
Long
1
EQ, a top quarterly gainer, rising +795%.Expect Uptrend reversalEquillium (EQ, $26.5) was one of top quarterly gainers, jumping +795.27% to $26.5 per share. Tickeron A.I.dvisor analyzed 383 stocks in the Biotechnology Industry over the last three months, and discovered that 298 of them (77.69%) charted an Uptrend while 85 of them (22.31%) trended down. Tickeron
Itolizumab Reduces Mortality in Patients Hospitalized with COVIDClinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19 Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon Biocon has received emergency use approval from Drugs Controller General of India for
it is bought with the rumor and it is sold with the news #EQequillium EQ-explodes-730%-positive-covid it is bought with the rumor and it is sold with the news “We note the trial in hospitalized COVID-19 patients was small (n=30), open-label and on top of standard of care, and little data were shared but according the Biocon/EQ press releases, the itolizumab

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Performance
Revenue to profit conversion
No revenue here
This company hasn't generated any revenue in the last financial year
Debt level and coverage
Earnings
Next:—
‪0‬

Trading & brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.4Very Good
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.3Good
Learn more

See all brokers